secwatch.observer — SEC 8-K summary
======================================

Issuer:     AVENUE THERAPEUTICS, INC. (ATXI)
CIK:        0001644963
Form:       8-K
Filed at:   2026-02-23T23:59:59+00:00
Accession:  0001104659-26-018582
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Avenue Therapeutics licenses ATX-04 from Duke University for Pompe disease; plans late-stage development
--------------------------------------------------------------------------------

- Exclusive worldwide license from Duke for ATX-04 (clenbuterol) to treat Pompe disease as adjunct to ERT.
- Upfront payment plus development, regulatory, and commercial milestone payments; tiered low single-digit royalty on net sales.
- Prior Duke clinical study showed ATX-04 improved six-minute walk distance, respiratory muscle strength, and reduced glycogen.
- Avenue to assume IND and FDA orphan drug designation for Pompe disease; plans late-stage development leveraging existing data.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1644963/000110465926018582/0001104659-26-018582-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1644963/000110465926018582/tm267053d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-018582

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer